表紙
市場調查報告書

Janus激酶(JAK)抑制劑的全球市場:2019年∼2023年

Global Janus Kinase (JAK) Inhibitors Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 900590
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
Janus激酶(JAK)抑制劑的全球市場:2019年∼2023年 Global Janus Kinase (JAK) Inhibitors Market 2019-2023
出版日期: 2019年07月27日內容資訊: 英文 133 Pages
簡介

全球Janus激酶JAK抑制劑市場,由於各種慢性疾病對JAK抑制劑的治療的使用增加,預期有很大的利益。由於對自體免疫障礙治療的JAK抑制劑的高效果,類風濕性關節炎,乾癬性關節炎及潰瘍性大腸炎的治療採用增加。 JAK抑制劑的使用相關研究,在臨床階段顯示重要的結果,對供應商來說產生市場潛力。同樣,由於對治療情形TNF抑制劑和白細胞介素抑制劑等未認證的治療方法優勢,對移植物抗宿主病(GVHD)治療的未滿足需求變高。為了應對高未滿足需求,全球JAK抑制劑市場供應商,開發新的GVHD治療藥。由於這樣的要素,預計全球Janus激酶(JAK)抑制劑市場在預測期間內以18%以上的年複合成長率擴大。

本報告提供全球Janus激酶(JAK)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • 自體免疫疾病
  • 腫瘤學
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 研究津貼的增加
  • 特別藥的指定
  • 策略性聯盟的增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31778

About this market

Global janus kinase (JAK) inhibitors are drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2. The inhibition of these enzymes helps interfere with the JAK-STAT signaling pathway, which has been found to play a key role in the development of various autoimmune disorders and cancer indications. Technavio's janus kinase (JAK) inhibitors market analysis considers sales from both autoimmune disorder and oncology. Our analysis also considers the sales of janus kinase (JAK) inhibitors in Asia, Europe, North America, ROW. In 2018, the autoimmune disorders segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high proven efficiency of these drugs will play a significant role in the autoimmune disorders segment to maintain its market position. Also, our global janus kinase (JAK) inhibitors market report also looks at factors such as increasing number of awareness campaigns, application in severe chronic indications, support from the growing healthcare insurance industry. However, the availability of alternative therapies, differential drug pricing, strong adverse effects may hamper the growth of the janus kinase (JAK) inhibitors industry over the forecast period.

Overview

Application in severe chronic indications

The global JAK inhibitors market is expected to benefit significantly from the rising use of JAK inhibitors to treat various chronic diseases. The high efficacy of JAK inhibitors for the treatment of autoimmune disorders has increased their adoption for the treatment of rheumatoid arthritis, psoriatic arthritis. and ulcerative colitis. Research on the use of JAK inhibitors has shown significant results in the clinical stages, which has created the market potential for the vendors. Similarly, the unmet need for the treatment of graft-versus-host disease (GVHD) is high as the treatment landscape is dominated by off-label of therapies such as TNF inhibitors and interleukin inhibitors. To address the high unmet need, vendors in the global JAK inhibitors market are developing novel drugs to treat GVHD. Such factors will lead to the expansion of the global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period.

Special drug designations

One of the major benefits that most JAK inhibitors have is the special drug designations given by regulatory bodies. Many drugs have received designations such as the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The orphan drug designation is given to a drug by the FDA when it is being developed to treat an indication that less than 200.000 people have in the US. Vendors that have received the orphan drug designation for their drug will get certain benefits associated with regulations and taxes. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global janus kinase (JAK) inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global janus kinase (JAK) inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading janus kinase (JAK) inhibitors manufacturers, that include Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.

Also, the janus kinase (JAK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Autoimmune disorders - Market size and forecast 2018-2023
  • Oncology - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research grants
  • Special drug designations
  • Rising number of strategic alliances

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Autoimmune disorders - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Pipeline of JAK inhibitors for autoimmune disorders
  • Exhibit 22: Autoimmune disorders - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Oncology - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Pipeline of JAK inhibitors for oncology
  • Exhibit 25: Oncology - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by application
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Astellas Pharma Inc. - Vendor overview
  • Exhibit 51: Astellas Pharma Inc. - Business segments
  • Exhibit 52: Astellas Pharma Inc. - Organizational developments
  • Exhibit 53: Astellas Pharma Inc. - Geographic focus
  • Exhibit 54: Astellas Pharma Inc. - Key offerings
  • Exhibit 55: Astellas Pharma Inc. - Key customers
  • Exhibit 56: Eli Lilly and Co. - Vendor overview
  • Exhibit 57: Eli Lilly and Co. - Business segments
  • Exhibit 58: Eli Lilly and Co. - Organizational developments
  • Exhibit 59: Eli Lilly and Co. - Geographic focus
  • Exhibit 60: Eli Lilly and Co. - Segment focus
  • Exhibit 61: Eli Lilly and Co. - Key offerings
  • Exhibit 62: Eli Lilly and Co. - Key customers
  • Exhibit 63: Incyte Corp. - Vendor overview
  • Exhibit 64: Incyte Corp. - Business segments
  • Exhibit 65: Incyte Corp. - Organizational developments
  • Exhibit 66: Incyte Corp. - Geographic focus
  • Exhibit 67: Incyte Corp. - Key offerings
  • Exhibit 68: Incyte Corp. - Key customers
  • Exhibit 69: Novartis AG - Vendor overview
  • Exhibit 70: Novartis AG - Business segments
  • Exhibit 71: Novartis AG - Organizational developments
  • Exhibit 72: Novartis AG - Geographic focus
  • Exhibit 73: Novartis AG - Segment focus
  • Exhibit 74: Novartis AG - Key offerings
  • Exhibit 75: Novartis AG - Key customers
  • Exhibit 76: Pfizer Inc. - Vendor overview
  • Exhibit 77: Pfizer Inc. - Business segments
  • Exhibit 78: Pfizer Inc. - Organizational developments
  • Exhibit 79: Pfizer Inc. - Geographic focus
  • Exhibit 80: Pfizer Inc. - Segment focus
  • Exhibit 81: Pfizer Inc. - Key offerings
  • Exhibit 82: Pfizer Inc. - Key customers
  • Exhibit 83: Validation techniques employed for market sizing
  • Exhibit 84: Definition of market positioning of vendors
Back to Top